EcoDrugPlus

Epoxide Hydrolase 2

Ensembl ID : ENSACLG00000008676
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSACLG00000022836
Gene Symbol: LOC113034677
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSACLG00000010392
Gene Symbol: ERBB2
1 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSACLG00000018831
Gene Symbol: ERBB4
3 Cross references
222 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSACLG00000009657
Gene Symbol: ERBB4A
1 Cross references
243 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSACLG00000019268
Gene Symbol: ESR1
1 Cross references
215 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSACLG00000009392
Gene Symbol: ESR2
3 Cross references
207 Possible Orthologues:

Estrogen Receptor Beta

Ensembl ID : ENSACLG00000027089
Gene Symbol: LOC113037293
3 Cross references
200 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSACLG00000011716
Gene Symbol: ESRRGA
1 Cross references
203 Possible Orthologues:

Exportin 1

Ensembl ID : ENSACLG00000015192
Gene Symbol: XPO1
3 Cross references
217 Possible Orthologues:

Exportin 1

Ensembl ID : ENSACLG00000015669
Gene Symbol: XPO1
1 Cross references
228 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSACLG00000019710
Gene Symbol: FDPS
3 Cross references
269 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).